, Volume 43, Issue 6, pp 820–836 | Cite as

Appetite Suppressants

A Review
  • Trevor Silverstone
Review Article


Centrally acting appetite suppressant drugs used in the treatment of obesity fall into 2 broad pharmacological categories; those which act via brain catecholamine pathways and those which act via serotonin pathways. Of the former group, amphetamine and phenmetrazine are no longer recommended because of their stimulant properties and addictive potential. The remaining drugs in this class include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine. All have been shown to reduce appetite and lower food intake, thereby helping obese patients more easily keep to a low-calorie diet and lose weight. They all have some sympatho-mimetic and stimulant properties. Anorectic drugs which promote serotonin neurotransmission have no such stimulant or sympathomimetic properties. They are fenfluramine, together with its recently introduced dextrorotatory stereoisomer dexfenfluramine, and fluoxetine. They reduce appetite and food intake and are effective in the treatment of obesity.

Anorectic drugs should be reserved for those who are clinically at risk from being overweight, and then only as part of a comprehensive weight-reducing programme including regular dietary counselling. Although current licensing regulations only allow their use over a relatively short period (12 to 16 weeks), clinical trials have shown them to be effective over longer periods, particularly in preventing weight regain. Of the compounds currently indicated for use in obesity, dexfenfluramine appears to have the most suitable pharmacological profile, although it should not be given to patients with a history of depression.

When used appropriately, appetite suppressants can be of real therapeutic benefit, and pose little risk.


Obese Patient Fluoxetine Fenfluramine Dexfenfluramine Phentermine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allen GS. A double-blind trial of diethylproprion hydrochloride, mazindol and placebo in the treatment of exogenous obesity. Current Therapy Research 22: 678–683, 1977Google Scholar
  2. Altschuler S, Conte A, Sebok M, Marlin R, Winick C. Three controlled trials of weight loss with phenylpropanolamine. International Journal of Obesity 6: 549–556, 1982PubMedGoogle Scholar
  3. Altschuler S, Frazer DL. Double-blind clinical evaluation of the anorectic activity of phenylpropanolamine hydyrochloride drops and placebo drops in the treatment of exogenous obesity. Current Therapy Research 40: 211–217, 1986Google Scholar
  4. American Medical Association. Drugs used in obesity. Drug Evaluations Subscriptions 3(6): 1–616, 1990Google Scholar
  5. Angel I. Central receptors and recognition sites mediating the effects of monoamines and anorectic drugs on feeding behaviour. Clinical Neuropharmacology 13: 361–391, 1990PubMedGoogle Scholar
  6. Ashwell M. A survey of patients’ views on doctors’ treatment of obesity. Practitioner 211: 653–661, 1973PubMedGoogle Scholar
  7. Atkinson RL, Greenway FL, Bray GA, Dahms WT, Molitch ME. Treatment of obesity: comparison of physician and non-physician therapists using placebo and anorectic drugs in a double-blind trial. International Journal of Obesity 1: 113–120, 1977PubMedGoogle Scholar
  8. Blackburn G, Morgan J, Lavin P, Noble R, Funder Burk F. Determinants of the pressor effect of phenylpropanolamine in healthy subjects. Journal of the American Medical Association 261: 3267–3272, 1989PubMedGoogle Scholar
  9. Blundell JE, Latham EM, McArthur RA. Structural analysis of the actions of amphetamine and fenfluramine on food intake and feeding behaviour in animals and in man. Current Medical Research and Opinion 6 (Suppl. 1): 34–54, 1979Google Scholar
  10. Bolding OT. Diethylproprion hydrochloride: an effective appetite suppressant. Current Therapy Research 16: 40–43, 1974Google Scholar
  11. Bradley MJ, Blum NJ, Scheib RK. Mazindol in obesity with known cardiac disease. Journal of International Medical Research 2: 347–354, 1974Google Scholar
  12. Bradley MH, Raines J. The effects of phenylpropanolamine hydrochloride in overweight patients with controlled stable hypertension. Current Therapy Research 46: 74–84, 1989Google Scholar
  13. Breum L, Astrup A, Anderson T, Lammert O, Nielsen E. The effect of long-tern) dexfenfluramine treatment on 24 hour energy expenditure in man, a double-blind placebo controlled study. International Journal of Obesity 13 (Suppl. 1): 150, 1989Google Scholar
  14. Breum L, Moller S, Bjerre U, Jacobsen S. Effect of fluoxetine on amino acids and macro-nutrient selection in obese patients. International Journal of Obesity 14 (Suppl. 2): 141, 1990Google Scholar
  15. British National Formulary. Appetite suppressants. British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1991Google Scholar
  16. Caccia S, Ballabio M, Guiso G, Rocchetti M, Garattini S. Species differences in the kinetics and metabolism of fenfluramine isomers. Archives of International Pharmacology 258: 15–28, 1982Google Scholar
  17. Campbell C, Bhalla IP, Steel JM, Duncan LJP. A controlled trial of phentermine in obese diabetic patients. Practitioner 218: 851–855, 1977PubMedGoogle Scholar
  18. Campbell DB. Plasma concentration of fenfluramine and its metabolite, norfenfluramine, following single and repeated oral administration. British Journal of Pharmacology 43: 465–469, 1971Google Scholar
  19. Carabillo EA. USA drug abuse warning network. In Garattini S & Samanin S (Eds) Central mechanisms of anorectic drugs, p. 461, Raven Press, New York, 1978Google Scholar
  20. Carlsson A. Amphetamine and brain catecholamines. In Costa E & Garattini S (Eds) Amphetamine and related compounds, pp. 289–300, Raven Press, New York, 1970Google Scholar
  21. Chait LD, Uhlenhuth EH, Johanson CE. Reinforcing and subjective effects of several anorectics on normal human volunteers. Journal of Pharmacology and Experimental Therapeutics 242: 777–783, 1987PubMedGoogle Scholar
  22. Craighead LW, Stunkard A, O’Brien RM. Behaviour therapy and pharmacotherapy for obesity. Archives of General Psychiatry 38: 763–768, 1981PubMedGoogle Scholar
  23. Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio E. Efficacy and safety of dexfenfluramine in obese patients. Clinical Neuropharmacology 11 (Suppl. 1): 5173–5178, 1988Google Scholar
  24. Douglas A, Douglas JG, Robertson CE, Munro JF. Plasma phentermine levels, weight loss and side-effects. International Journal of Obesity 7 (Suppl. 6): 591–595, 1983PubMedGoogle Scholar
  25. Ferguson JM, Feighner JP. Fluoxetine induced weight loss in overweight non-depressed subjects. International Journal of Obesity 11 (Suppl. 3): 163–170, 1987PubMedGoogle Scholar
  26. Finer N, Craddock D, Lavielle R, Keen H. Dextrofenfluramine in the treatment of refractory obesity. Current Therapy Research 38: 847–854, 1985Google Scholar
  27. Finer N, Craddock D, Lavielle R, Keen H. Prolonged weight loss with dexfenfluramine treatment in obese patients. Diabetes and Metabolism 13: 598–602, 1987Google Scholar
  28. Finer N, Finer S, Naoumova R. Dexfenfluramine after successful weight reduction on a very low calorie diet (VLCD). International Journal of Obesity 13 (Suppl. 2): 91–93, 1989PubMedGoogle Scholar
  29. Fink M, Shapiro DM, Itil TM. EEG profiles of fenfluramine, amobarbital and dextroamphetamine in normal volunteers. Psychopharmacologia 22: 369–383, 1971PubMedGoogle Scholar
  30. Fuller RW, Wong DT. Fluoxetine and serotoninergic appetite suppressant drugs. Drug Development Research 17: 1–15, 1989Google Scholar
  31. Gagnon M, Bordileau J, Tetrault L. Fenfluramine: study of its central action through its effects on sleep. International Journal of Clinical Pharmacology 1: 74–82, 1969Google Scholar
  32. Garattini S, Bizzi A, Caccia S, Mennini T, Samanin R. Progress in assessing the role of serotonin in the control of food intake. Clinical Neuropharmacology 11 (Suppl. 1): 58–532, 1988Google Scholar
  33. Garrow JS. Obesity and related diseases, pp. 169–173, Churchill Livingstone, Edinburgh, 1988Google Scholar
  34. Giordano G, Marago M, Bompiani G, Descovich GC, Papalia D. Efficacy and treatment of dexfenfluramine in the treatment of simple obesity: multicentre Italian study. Clinical Diabetology 17: 81–89, 1990Google Scholar
  35. Goodall E, Corney R, Stanton R, Browne PB. Changes in food preference in premenstrual syndrome. 1st European Congress on Obesity, Stockholm, 1988Google Scholar
  36. Goodall E, Feeney S, McGuirk J, Silverstone T. A comparison of the effects of d- and 1-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects. Psycho-pharmacology 106: 221–227, 1992Google Scholar
  37. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, et al. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. British Journal of Psychiatry 153: 208–213, 1988PubMedGoogle Scholar
  38. Goodall E, Silverstone T. Differential effect of d-fenfluramine and metergoline on food intake in human subjects. Appetite 11: 215–228, 1988PubMedGoogle Scholar
  39. Goodman R, Wright J, Barlascini C, McKenney J, Lambert C. The effect of phenylpropanolamine on ambulatory blood pressure. Clinical Pharmacology and Therapeutics 40: 144–147, 1986PubMedGoogle Scholar
  40. Gotestam KG, Gunne LM. Subjective effects of two anorexigenic agents fenfluramine and AN 448 in amphetamine dependent subjects. British Journal of Addiction 67: 39–44, 1972Google Scholar
  41. Grapin B, Cohen A. Drug therapy in simple obesity: controlled trial of mazindol. Internal Medical Digest 9: 15–21, 1974Google Scholar
  42. Greenway F. A double-blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo. Clinical Therapeutics 11: 584–589, 1989PubMedGoogle Scholar
  43. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142–1145, 1989PubMedGoogle Scholar
  44. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, et al. Effect of withdrawal of dexfenfluramine on bodyweight and food intake after one year’s administration. International Journal of Obesity 14 (Suppl. 2): 48, 1990Google Scholar
  45. Hedges A. AN 448 on critical flicker frequency and heart rate in man. South African Medical Journal 46: 139, 1972PubMedGoogle Scholar
  46. Hill AJ, Blundell JE. Food selection, body weight and the premenstrual syndrome (PMS) — effect of d-fenfluramine. Appetite 12: 215, 1989Google Scholar
  47. Hill AJ, Blundell JE. Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. International Journal of Obesity 14: 219–233, 1990PubMedGoogle Scholar
  48. Hoebel BG, Cooper J, Kamin MC, Willard D. Appetite suppression by phenylpropanolamine in humans. Obesity/Bariatric Medicine 4: 192–197, 1975Google Scholar
  49. Hoekenga MT, O’Dillon RH, Leyland HM. A comprehensive review of diethylpropion hydrochloride. In Garattini S & Samanin R (Eds) Central mechanisms of anorectic drugs, Raven Press, New York, 1978Google Scholar
  50. Holmstrand J, Jonsson J. Subjective effects of two anorexogenic agents — fenfluramine and AN 448 in normal subjects. Postgraduate Medical Journal 57: 183–186, 1975Google Scholar
  51. Innes JA, Watson ML, Ford MJ, Munro JF, Stoddart M. Plasma fenfluramine levels, weight loss and side effects. British Medical Journal 2: 1322–1325, 1977PubMedGoogle Scholar
  52. Kalb SW. The effect of amphetamine (Benzadrine) sulfate pro-padrine hydrochloride and propadrine hydrochloride in combination with sodium devinai on the appetite of obese patients. Journal of the Medical Society of New Jersey 39: 584–586, 1942Google Scholar
  53. Kolanowski J, Younis L, Vanbutsele R, Detry JM. Effects of d-fenfluramine treatment on body weight, blood pressure and adrenergic activity in obese subjects with moderate hypertension. 1st European Congress on Obesity, 288, Stockholm, 1988Google Scholar
  54. Kutnowski M, Daubresse J, Friedman H, Kolanowski J, Krzentowski G. Eight weeks fluoxetine therapy in obese patients with impaired glucose tolerance. International Journal of Obesity 14 (Suppl. 2): 48, 1990Google Scholar
  55. Kyriakides M, Silverstone T. Comparison of the effects of d-amphetamine and fenfluramine on hunger and food intake in man. Neuropharmacology 18: 1007–1008, 1979PubMedGoogle Scholar
  56. Lasagna L. Anorectic activity: phenylpropanolamine — a review, pp. 132–146, Wiley — Interscience, New York, 1988Google Scholar
  57. Lawson AAH, Strong JA, Roscoe P, Gibson A. Comparison of fenfluramine and metformin in treatment of obesity. Lancet 1: 437–441, 1970Google Scholar
  58. Leibowitz SF. The role of serotonin in eating disorders. Drugs 39 (Suppl. 3): 33–48, 1990PubMedGoogle Scholar
  59. Levine L, Enas G, Thompson W, Byyny R, Daver A. Use of fluoxetine, a selective serotonin-uptake inhibitor in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). International Journal of Obesity 13: 635–645, 1989PubMedGoogle Scholar
  60. Liebson I, Bigelow G, Griffiths R, Funderburk F. Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended over the counter dose levels. Journal of Clinical Pharmacology 27: 685–693, 1987PubMedGoogle Scholar
  61. McGuirk J, Silverstone T. The effect of the 5-HT reuptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. International Journal of Obesity 14: 361–372, 1990aPubMedGoogle Scholar
  62. McGuirk J, Silverstone T. Effects of fluoxetine on appetite, food intake and body weight in obese subjects. International Journal of Obesity 14 (Suppl. 2): 141, 1990bGoogle Scholar
  63. McKay RHG. Long-term use of diethylpropion in obesity. Current Medical Research 1: 489–493, 1973Google Scholar
  64. McQuarrie HGD. Clinical assessment of the use of an anorectic drug in a total weight reduction programme. Current Therapy Research 17: 437–445, 1975Google Scholar
  65. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 43: 713–733, 1992PubMedGoogle Scholar
  66. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M. A double-blind, placebo controlled trial of fluoxetine plus behaviour modification in the treatment of obese binge-eaters and non-binge eaters. American Journal of Psychiatry 147: 876–881, 1990PubMedGoogle Scholar
  67. Miach P, Thomson W, Doyle A, Louis W. Double-blind crossover evaluation of mazindol in the treatment of obese hypertensive patients. Medical Journal of Australia 2: 378, 1976PubMedGoogle Scholar
  68. Morgan JP, Funderburg FR, Blackburn GL, Noble R. Subjective profile of phenylpropanolamine: absence of stimulant or euphorigenic effects at recommended dose levels. Journal of Clinical Psychopharmacology 9: 33–38, 1989PubMedGoogle Scholar
  69. Munger R, Lamelle R, Arnaud O, Schutz O, Jecquier E. Enhanced diet induced thermogenesis in humans after administration of dexfenfluramine. 1st European Congress on Obesity, Stockholm, 1988Google Scholar
  70. Munro JF. The clinical use of anti-obesity agents. In Munro JF (Eds) The treatment of obesity, pp. 85–121, MTP, Lancaster, 1979Google Scholar
  71. Munro JF, Ford M. Drug treatment of obesity. In Silverstone T (Eds) Drugs and appetite, pp. 125–157, Academic Press, London, 1982Google Scholar
  72. Munro JF, Seaton DA, Duncan LJP. Treatment of refractory obesity with fenfluramine. British Medical Journal 11: 624–625, 1966Google Scholar
  73. National Institutes of Health Consensus Development Panel. Health implications of obesity. Annals of Internal Medicine 103: 1073–1077, 1985Google Scholar
  74. Noble R. A six-month study of the effects of dexfenfluramine on partially successful dieters. Current Therapy Research 47: 612–619, 1990Google Scholar
  75. Onishi T. Clinical evaluation of mazindol, an anorexiant, on obesity. International Journal of Obesity 14 (Suppl. 2): 34, 1990Google Scholar
  76. Oswald I, Jones HS, Mannerheim JE. Effects of two slimming drugs on sleep. British Medical Journal 1: 796–799, 1968PubMedGoogle Scholar
  77. Pietrusko R, Stunkard A, Brownell K, Campbell DB. Plasma fenfluramine levels, weight loss and side effects: a failure to find a relationship. International Journal of Obesity 6(6): 567–572, 1982PubMedGoogle Scholar
  78. Pijl H, Koppeschaar H, Meinders A, Willekens F, Op De Kamp I. Fluoxetine and dietary intake and composition. International Journal of Obesity 13 (Suppl. 1): 131–145, 1989Google Scholar
  79. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity and diabetes mellitus. Drugs 10: 241–323, 1975PubMedGoogle Scholar
  80. Richard BW, Lasagna L. Anorectic drugs: drug policy making at the state level. Journal of Clinical Pharmacology 28: 395–400, 1988Google Scholar
  81. Rosenstock J, Cercone S, Koffler M, Ramirez L, Raskin P. The effects of the serotonin reuptake inhibitor fluoxetine on weight loss, glycaemic control and lipid levels in non-insulin dependent diabetes mellitus. Diabetes 36 (Suppl. 1): 66A, 1987Google Scholar
  82. Royal College of Physicians. Obesity. Journal of the Royal College of Physicans 17: 3–58, 1983Google Scholar
  83. Samanin R, Garattini S. Neuropharmacology of feeding. In Silverstone T (Eds) Drugs and appetite, pp. 23–39, Academic Press, London, 1982Google Scholar
  84. Scalfi L, D’Arrigo E, Carandente V, Coztorti A, Contaldo F. The effect of d-fenfluramine on BMR and post prandial thermogenesis in obese subjects. International Journal of Obesity 13 (Suppl. 1): 142, 1989Google Scholar
  85. Scheen AJ, Paolisso G, Salvatore T, Lefebvre PJ. Dexfenfluramine reduces insulin resistance independently of weight reduction in obese type 2 (non-insulin-dependent) diabetic patients. Diabetologica 31: 640A 1988Google Scholar
  86. Schteingart D. Effectiveness of phenylpropanolamine as an adjunct in the dietary management of obesity. International Journal of Obesity 14 (Suppl. 2): 48, 1990Google Scholar
  87. Silverstone T. The anorectic effect of a long-acting preparation of phentermine (Duromine). Psychopharmacoligia 25: 315–320, 1972Google Scholar
  88. Silverstone JT. Intermittent treatment with anorectic drugs. Practitioner 212: 245–252, 1974Google Scholar
  89. Silverstone JT, Buckle RM. Obesity in diabetes: some considerations on treatment. American Journal of Clinical Nutrients 19: 158–167, 1966Google Scholar
  90. Silverstone JT, Cooper-RM, Begg RR. A comparative trial of fenfluramine and diethylpropion in obesity. British Journal of Clinical Practitioners 24 (Suppl. 10): 423–425, 1970Google Scholar
  91. Silverstone JT, Fincham J, Campbell DB. The anorectic activity of fenfluramine. Postgraduate Medical Journal 51 (Suppl. 1): 171–174, 1975PubMedGoogle Scholar
  92. Silverstone T, Kyriakides M. Clinical Pharmacology of appetite. In Silverstone T (Eds) Drugs and appetite, pp. 93–123, Academic Press, London, 1982Google Scholar
  93. Silverstone T, Smith G, Richards R. A comparative evaluation of dextrofenfluramine and dl-fenfluramine on hunger, food intake, psychomotor function and side effects in normal human subjects. In Bender A & Brookes L (Eds) Body weight control, pp. 240–246, Churchill Livingstone, Edinburgh, 1987Google Scholar
  94. Silverstone JT, Turner P, Humpherson PL. Direct measurement of the anorectic activity of diethylpropion (Tenuate Dospan). Journal of Clinical Pharmacology 8 (Suppl. 3): 172–179, 1968Google Scholar
  95. Striwatanakul K, Yuthavong K, Kominor S. Double-blind study to determine the efficacy and safety of dexfenfluramine in the treatment of obesity. European Journal of Clinical Pharmacology 36 (Suppl): A322, 1989Google Scholar
  96. Steel JM, Munro JF, Duncan LJP. A comparative trial of different regimes of fenfluramine and phentermine in obesity. Practitioner 211: 232–236, 1973PubMedGoogle Scholar
  97. Stunkard A, Rickeis K, Hesbacher P. Fenfluramine in the treatment of obesity. Lancet 1: 503–505, 1973PubMedGoogle Scholar
  98. Sullivan AC, Cornai K. Pharmacological treatment of obesity. International Journal of Obesity 2: 167–189, 1978PubMedGoogle Scholar
  99. Tauber-Lassen E, Damsbo P, Enrikson JE, Palmvig B, Beck-Bielsen H. Improvement of glycaemic control and weight loss in type 2 (non-insulin-dependent diabetics) after one year of dexfenfluramine treatment. Diabetologica 33: A230, 1990Google Scholar
  100. Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled randomised double-blind prospective study. Current Therapy Research 14: 726–738, 1972Google Scholar
  101. Tuominen S, Hietula M, Kuusankoski M. Double-blind trial comparing fenfluramine, phentermine and dietary advice on treatment of obesity. International Journal of Obesity 14 (Suppl. 2): 138, 1990Google Scholar
  102. Turner P. Peripheral mechanisms of action of fenfluramine. Current Medical Research and Opinion 6 (Suppl. 1): 101–106, 1979Google Scholar
  103. Turner P. Dexfenfluramine: its place in weight control. Drugs 39 (Suppl. 3): 53–62, 1990PubMedGoogle Scholar
  104. Van Gaal L, Vansant G, Vandevoorde K, Biasi B, De Leevw I. Long-term evaluation of dex-fenfluramine treatment in obese women. International Journal of Obesity 13 (Suppl. 1): 141, 1989Google Scholar
  105. Weintraub M, Ginsberg G, Stein E, Sundaresan P, Schuster B. Phenylpropanolamine OROS (Acutrim) vs placebo in combination with calorie restriction and physician managed behaviour modification. Clinical Pharmacology and Therapeutics 39: 501–509, 1986PubMedGoogle Scholar
  106. Weintraub M, Sriwatanakul K, Sundaresan PR, Weis OF, Dorn IM. Extended release fenfluramine: patient acceptance and efficacy of evening dose. Clinical Pharmacology and Therapeutics 33: 621–627, 1983PubMedGoogle Scholar
  107. Weintraub M, Taves D, Hasday J, Mushlin A, Lockwood DH. Determinants of response to anorexiants. Clinical Pharmacology and Therapeutics 30: 528–535, 1981PubMedGoogle Scholar
  108. Wing RR, Jeffrey RW. Outpatient treatments of obesity: a comparison of methodology and clinical results. International Journal of Obesity 3: 261–279, 1979PubMedGoogle Scholar
  109. Wise S. Fluoxetine, efficacy and safety in treatment of obese type 2 (non-insulin-depeendent) diabetes. Diabetologica 32: 557A, 1989Google Scholar
  110. Wurtman J, Wurtman R, Reynolds S, Tsay R, Chew B. Fenfluramine suppresses snack intake among carbohydrate cravers but not among non-carbohydrate cravers. International Journal of Eating Disorders 6: 687–699, 1987Google Scholar
  111. Zerbe RL. Safety of fluoxetine in the treatment of obesity. International Journal of Obesity 11 (Suppl. 3): 191–199, 1987PubMedGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Trevor Silverstone
    • 1
  1. 1.Medical College of St Bartholomew’s HospitalUniversity of LondonLondonEngland

Personalised recommendations